Health News

If you’ve been following the conversation around GLP-1 weight loss medications, this past week brought two significant developments — one exciting, one cautionary — that every patient in our community deserves to understand. On March 19, 2026, the FDA approved a new higher-dose version of Wegovy called Wegovy HD. And just days before that, the FDA sent warning letters to 30 telehealth companies for making false claims about compounded GLP-1 products. As your pharmacist, I want to walk you through both.

What Is Wegovy HD, and What Did the Research Show?

Wegovy HD is a 7.2-milligram dose of semaglutide — the same active ingredient in the original Wegovy (2.4 mg) — but at a significantly higher strength. Novo Nordisk, the drug’s manufacturer, studied this higher dose in the STEP UP trial, and the results were substantial. Participants who took Wegovy HD lost approximately 19% of their body weight, or around 47 pounds on average. That’s meaningful improvement over the 2.4 mg dose, which had previously shown roughly 15% body weight reduction in earlier studies.

The FDA accepted the application and approved the drug in just 54 days — a notably fast turnaround. Wegovy HD is expected to be available at pharmacies across the country, including here in Southeast Georgia, starting in April 2026.

It’s important to note who is eligible for this higher dose. According to the prescribing guidance, Wegovy HD is intended for adults with obesity who have already tolerated the standard 2.4 mg dose for at least four weeks, and for whom additional weight reduction is clinically indicated by their physician. It is not a starting dose — it is a step-up option for appropriate patients under medical supervision.

More Weight Loss — But Also More Side Effects

The STEP UP trial results were promising, but the side effect picture is also more pronounced at the higher dose, and I think it’s worth being transparent about that.

According to findings reported in medical news coverage of the approval, more than 70% of patients taking Wegovy HD experienced gastrointestinal side effects such as nausea, vomiting, or constipation — compared to just over 60% on the 2.4 mg dose and about 43% of those on placebo. That’s a meaningful jump.

Additionally, approximately 23% of patients on Wegovy HD reported unusual skin sensations like burning or tingling, compared to only 6% on the lower dose and less than 1% on placebo. This is a newly documented side effect profile that patients and prescribers will need to monitor closely.

None of this means Wegovy HD is unsafe — the FDA reviewed the full data and determined the benefits outweigh the risks for appropriate patients. But it reinforces why these medications should always be managed in partnership with your physician and pharmacist, not through an online subscription with minimal follow-up.

Compounded GLP-1s: Why They Existed, and What’s Changed

To understand the current regulatory picture, it helps to understand why compounded GLP-1 medications existed in the first place — because there were genuinely good reasons for them.

When semaglutide and tirzepatide were placed on the FDA’s official drug shortage list, compounding pharmacies were legally authorized to produce copies of those medications to help meet patient demand. This served a real need. Many patients could not access or afford brand-name Wegovy, Ozempic, Zepbound, or Mounjaro during the shortage period. Compounded formulations also allowed for adjustments in inactive ingredients — something that can matter for patients who experience tolerability issues with a specific commercial formulation. At Walker Pharmacy, we dispensed compounded semaglutide during this period ourselves, under FDA authorization and guidance, because our patients needed access to care.

What has changed is that the FDA has officially declared the shortage over for both semaglutide and tirzepatide. Under federal law, once a drug is removed from the shortage list, the legal basis for compounders to produce copies of that drug for general dispensing expires as well. This isn’t a statement that compounding pharmacies did anything wrong during the shortage — most didn’t. It’s simply how the regulatory framework works.

The 30 warning letters sent by the FDA in February 2026 — reported by STAT News and Fierce Pharma — were specifically directed at telehealth companies making false equivalency claims: implying their compounded products were identical to FDA-approved Wegovy or Ozempic, and obscuring the actual source of the medication. Those are marketing violations on top of the underlying shortage-list issue. The companies cited weren’t penalized simply for compounding during a shortage — they were penalized for continuing after the shortage ended and for misleading patients about what they were receiving.

A Pharmacist’s Perspective

I want to share my honest take on both of these developments, the way I would if you walked up to the counter at our Statesboro or Lyons location.

On Wegovy HD: the STEP UP trial data is real, and for patients who have struggled to reach their weight goals on the 2.4 mg dose, this could be a meaningful option. But the higher side effect burden — especially the GI symptoms and the new skin sensations — means this is a medication that warrants close monitoring. This isn’t something to pursue casually. If you’re currently on a GLP-1 medication and wondering whether Wegovy HD might be right for you, please talk to your doctor first. And then ask your pharmacist what to watch for when you pick it up.

On compounded GLP-1 products: I want to be transparent here. Walker Pharmacy dispensed compounded semaglutide last year during the shortage, under FDA authorization, because our patients needed it and we were committed to helping them access care. We made the decision to stop when the shortage was declared over — that’s the right thing to do under the law. I’m not going to tell you that compounded GLP-1s were a bad thing. For many patients, they were a lifeline.

What I will say is that the commercial product landscape has improved significantly. Manufacturer savings programs have come a long way, and the price gap that made compounded versions attractive has narrowed considerably for many patients. If you were on a compounded version and are weighing your next steps, the savings programs offered directly by Novo Nordisk and Eli Lilly are worth a look:

• Wegovy (semaglutide for weight management) — Wegovy Savings Offer via Novo Nordisk
• Ozempic (semaglutide for type 2 diabetes) — Ozempic Savings Card via Novo Nordisk
• Zepbound (tirzepatide for weight management) — Zepbound Savings Card via Eli Lilly
• Mounjaro (tirzepatide for type 2 diabetes) — Mounjaro Savings Card via Eli Lilly

Eligibility and savings amounts vary depending on your insurance situation. Our pharmacists are glad to help you sort through your options — that’s a conversation we’re always happy to have at the counter.

GLP-1 medications are genuinely useful tools, and the science behind them is real. But they deserve the same care and oversight as any other chronic medication.

Is Wegovy HD available at Walker Pharmacy?

Wegovy HD is expected to be available at pharmacies nationwide starting in April 2026. Our team at Walker Pharmacy will be stocking and dispensing it as soon as it becomes available in our area. Call us or stop by and we’ll help you check your insurance coverage and any available patient assistance programs.

Can I still get compounded semaglutide from an online pharmacy?

With the FDA’s official declaration that semaglutide and tirzepatide are no longer in shortage, the legal authorization for compounding pharmacies to produce and dispense these medications for general use has expired. Compounded GLP-1s dispensed during the shortage were legal at the time — the regulatory framework simply reflects the current supply situation. If you have been on a compounded version and are weighing your next steps, speak with your prescriber and ask your pharmacist about the manufacturer savings programs listed in the Pharmacist’s Perspective section above. Many patients are finding the commercial products more financially accessible than they expected.

What are the side effects I should watch for on GLP-1 medications?

The most commonly reported side effects with semaglutide include nausea, vomiting, diarrhea, and constipation — especially when doses are first increased. Wegovy HD also showed higher rates of unusual skin sensations (burning or tingling) in clinical trials. Anyone experiencing severe abdominal pain, vision changes, signs of allergic reaction, or any unusual symptoms should contact their doctor or seek care immediately. Always let your pharmacist know all the medications you’re taking so they can screen for interactions.

How is Wegovy HD different from regular Wegovy?

Wegovy HD contains 7.2 mg of semaglutide, compared to the standard 2.4 mg dose of Wegovy. In the STEP UP clinical trial, the higher dose produced roughly 19% body weight reduction, compared to about 15% with the 2.4 mg dose. It is intended for patients who are already on Wegovy and need additional weight management, not as a first-line therapy. The higher dose also comes with a higher rate of gastrointestinal and skin-related side effects.

Should I switch from Ozempic to Wegovy HD for better weight loss?

Ozempic and Wegovy both contain semaglutide, but they are approved for different indications and come in different dose forms. Switching medications or doses is a decision that should be made with your physician based on your full health history. Your pharmacist can explain the differences and help coordinate with your care team — that’s exactly what we’re here for.

If you have questions about GLP-1 medications, want to review your current prescriptions, or are curious about your coverage options for weight management therapies, our pharmacists are ready to help. Come talk to us at any of our four Walker Pharmacy locations in Statesboro, Brooklet, and Lyons — or visit us online at walkerpharmacy.com to transfer your prescriptions and get started with a pharmacist you can actually talk to.

This article is for informational purposes only and does not constitute medical or health advice. Always consult your physician or pharmacist before making changes to your health regimen.

— Jordan Walker, PharmD | Owner, Walker Pharmacy
Serving Statesboro, Brooklet, and Lyons, Georgia — Bulloch and Toombs Counties